Bing Center for Waldenstrom's Macroglobulinemia - Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom's Macroglobulinemia

You are here: Home

Publications

Pub-2011

Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom's Macroglobulinemia

Can't see this document? Click Here

Legal | Privacy